- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01815125
Ondansetron for Pediatric Mild Traumatic Brain Injury
Ondansetron for Pediatric Mild Traumatic Brain Injury; a Pilot Randomized Controlled Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3T1C5
- CHU Sainte-Justine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children aged between 8 and 17 years old. This will be limited to this small spectrum of age to insure better homogeneity in the evaluation of the participants and streamlining of outcome measures. Also, this is the age group for which our measurement tool has been validated.
Occurrence of a mTBI as defined by the presence of a head trauma, a Glasgow coma scale of 13 to 15 and at least one of the three following criteria4 :
- Any period of loss of consciousness.
- Any loss of memory for events immediately before or after the accident.
- Any alteration in mental state at the time of the accident (eg, feeling dazed, disoriented).
And the absence of the following criteria:
- Post-traumatic amnesia greater than 24 hours.
- Glasgow Coma Scale < 13, 30 minutes post accident.
- The trauma occurred in the preceding 24 hours.
Exclusion Criteria:
1. Inability to obtain a proper written informed consent (language barrier, absence of a parental authority, developmental delay, intoxication, patient too confuse to consent according to the treating physician).
2. Known allergic reaction or intolerance to ondansetron. 3. Known rhythm or cardiac problem, or history of sudden death in the proximal family 4. Patients who are taking a medication which could increase the QT interval. 5. Patients who received ondansetron in the previous 24 hours 6. Any abnormality on radiological studies, including any bleeding in the brain or skull fracture.
7. Multi-system injuries with treatment requiring admission to hospital or procedural sedation in the ED.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Ondansetron
The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department.
The dosage will be 8 mg.
|
The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department.
The dosage will be 8 mg.
Other Names:
|
PLACEBO_COMPARATOR: Placebo
The control group will receive a similar looking/ tasting pill of placebo.
|
placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Persistence of post concussive symptoms
Time Frame: 1 week post intervention
|
Persistence of post concussive symptoms will be defined by an increase from pre-concussion baseline of at least 3 symptoms of the Post Concussion Symptom Inventory (PCSI).
The PCSI is a self-report tool evaluating the presence of 25 symptoms (on a 3-point likert scale) for children 8-12 and 26 symptoms on a (7-point likert scale) for children 13-17 years.
An increase of two points or more from pre-injury in any symptom is considered clinically significant.
|
1 week post intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean number of PCSI symptoms
Time Frame: one week and month following intervention
|
one week and month following intervention
|
|
Mean number of school days missed
Time Frame: one month following intervention
|
one month following intervention
|
|
Number of days of sport activity restriction
Time Frame: 1 month following intervention
|
1 month following intervention
|
|
Time before full recovery
Time Frame: One month following intervention
|
According to the parents
|
One month following intervention
|
Healthcare utilization
Time Frame: One month following intervention
|
Proportion of participants who consulted a health resource.
|
One month following intervention
|
Side effects
Time Frame: one week and month following intervention
|
Side effects will include, in addition to symptoms related to mTBI,proportion of participants who complained of diarrhea or constipation (binary answer).
|
one week and month following intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants who complete the assessment at one week following intervention
Time Frame: One week following intervention
|
the main objective of the pilot study is to evaluate the feasibility of the randomized controlled trial.
Accordingly, the primary outcome of the pilot study will be the proportion of participants who complete the assessment at one week following intervention
|
One week following intervention
|
Proportion of eligible children who were not included
Time Frame: At baseline
|
This is the proportion of eligible children who were not included and reasons for non-inclusion.
|
At baseline
|
Compliance with study medication
Time Frame: One week following intervention
|
Proportion of patients who tolerated their medication and proportion of patients randomized to the control group who received ondansetron
|
One week following intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jocelyn Gravel, MD, CHU Sainte-JUstine, University of Montreal
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Craniocerebral Trauma
- Trauma, Nervous System
- Head Injuries, Closed
- Wounds, Nonpenetrating
- Brain Injuries
- Wounds and Injuries
- Brain Injuries, Traumatic
- Brain Concussion
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Dermatologic Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin Antagonists
- Anti-Anxiety Agents
- Antipruritics
- Ondansetron
Other Study ID Numbers
- ZOF2013
- 9427-c2686-28c (OTHER: Health Canada)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Traumatic Brain Injury
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
Hospital Sirio-LibanesUniversity of Sao Paulo; Ministry of Health, Brazil; Hospital Sao Rafael; PROAD... and other collaboratorsRecruitingBrain Injury Traumatic Severe | Brain Injury Traumatic Moderate | Post Traumatic EpilepsyBrazil
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
Children's Hospital Medical Center, CincinnatiUniversity of CincinnatiCompletedBrain Injury Traumatic MildUnited States
-
Institut National de la Santé Et de la Recherche...Institut National de Recherche en Informatique et en AutomatiqueNot yet recruitingTBI (Traumatic Brain Injury)France
-
BrainScope Company, Inc.RecruitingTBI (Traumatic Brain Injury) | Concussion, Brain | MTBI - Mild Traumatic Brain Injury | Closed Head InjuryUnited States
-
University of Sao Paulo General HospitalUnknownTraumatic Brain Injury | Severe Brain Injury | Closed Traumatic Brain InjuryBrazil
-
Queen Mary University of LondonCompleted
-
Northeastern UniversityBrandeis UniversityRecruitingTraumatic Brain Injury | Mild Traumatic Brain Injury | TBI | Moderate Traumatic Brain InjuryUnited States
Clinical Trials on Ondansetron
-
Merck Sharp & Dohme LLCCompletedChemotherapy-Induced Nausea and Vomiting
-
Seoul National University Bundang HospitalRecruiting
-
Tanta UniversityRecruitingCaesarean Section | Postoperative Nausea and Vomiting | Ondansetron LozengeEgypt
-
Halozyme TherapeuticsCompleted
-
Aquestive TherapeuticsCompleted
-
Washington University School of MedicineCompleted
-
General Hospital of Ningxia Medical UniversityCompleted
-
Merck Sharp & Dohme LLCCompletedChemotherapy-Induced Nausea and Vomiting